文献速递MDS 与骨髓增殖性肿瘤

地西他滨与西达尿苷口服固定剂量组合治疗骨髓增生异常综合征:多中心、开放标签、剂量递增1期研究

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
PubMed 文献 · Lancet Haematol · 2019-01-01

这项1期剂量递增研究纳入44例骨髓增生异常综合征或慢性粒单核细胞白血病患者,评估口服地西他滨联合西达尿苷的药代动力学、安全性和疗效。结果显示口服地西他滨30 mg或40 mg联合西达尿苷100 mg的平均AUC最接近静脉地西他滨,安全性相似,临床缓解与静脉地西他滨5天治疗相似。

要点

  • 口服地西他滨联合西达尿苷可使地西他滨AUC呈剂量依赖性增加,30 mg和40 mg联合西达尿苷100 mg的AUC最接近静脉地西他滨。
  • 最常见≥3级不良事件为血小板减少(41%)、中性粒细胞减少(30%)、贫血(25%)。
  • 4例(9%)患者因不良事件死亡,均认为与药物无关。

核心结论

  • 口服地西他滨联合西达尿苷可模拟静脉地西他滨的药代动力学,安全性相似,并呈剂量依赖性去甲基化,临床缓解与静脉地西他滨5天治疗相似。
  • 作者认为有必要进一步研究地西他滨联合西达尿苷作为胃肠外治疗的替代方案或与其他新型口服药物联合用于髓系疾病。

研究设计与样本

  • 多中心、开放标签、剂量递增1期研究,纳入44例(筛选75例)既往治疗或新诊断的骨髓增生异常综合征或慢性粒单核细胞白血病患者,43例可评估。
  • 起始剂量为地西他滨20 mg和西达尿苷40 mg,治疗周期28天,每周期给药5天;第1周期第-3天口服队列定义剂量地西他滨,第1天静脉输注地西他滨20 mg/m2,第2-5天口服地西他滨加西达尿苷;第2周期及以后第1-5天口服给药。
  • 先递增西达尿苷剂量,当西达尿苷对CDA抑制接近最大效应后递增地西他滨剂量;若口服地西他滨平均AUC低于同队列静脉地西他滨的90%且未观察到剂量限制性毒性则递增剂量。
  • 剂量限制性毒性定义为与基础疾病无关的≥3级非血液学毒性或持续超过14天的4级血液学毒性。
  • 当达到以静脉地西他滨确定的AUC目标范围且剂量安全时,将最接近静脉地西他滨暴露的队列扩展至18例可评估患者。

主要发现

  • 2014年10月28日至2015年11月13日入组44例患者,43例可评估;队列1-4各6例可评估患者,队列5包括19例患者(13例扩展)。
  • 随着队列剂量递增,地西他滨AUC和血浆峰浓度呈剂量依赖性增加;与静脉地西他滨相比毒性未见明显增加。
  • 地西他滨30 mg和40 mg联合西达尿苷100 mg的第5天平均地西他滨AUC分别为146 ng×h/mL和221 ng×h/mL,最接近静脉地西他滨的平均AUC 164 ng×h/mL。
  • 最常见≥3级不良事件为血小板减少(18/44,41%)、中性粒细胞减少(13/44,30%)、贫血(11/44,25%)、白细胞减少(7/44,16%)、发热性中性粒细胞减少(7/44,16%)和肺炎(7/44,16%)。
  • 4例(9%)患者因不良事件死亡,均认为与药物无关;3例(7%)患者在停药超过30天后死亡,原因为疾病进展(2例,5%)和呼吸衰竭(1例,2%)。

关键数值与推荐

  • 口服地西他滨30 mg联合西达尿苷100 mg的平均第5天AUC为146 ng×h/mL。
  • 口服地西他滨40 mg联合西达尿苷100 mg的平均第5天AUC为221 ng×h/mL。
  • 静脉地西他滨的平均AUC为164 ng×h/mL。
  • 剂量递增标准:口服地西他滨平均AUC低于同队列静脉地西他滨的90%且无剂量限制性毒性。
  • 剂量限制性毒性定义:≥3级非血液学毒性或持续超过14天的4级血液学毒性且与基础疾病无关。

临床怎么用

  • 原文未据此给出临床推荐。
  • 作者认为有必要进一步研究地西他滨联合西达尿苷作为胃肠外治疗的替代方案或与其他新型口服药物联合用于髓系疾病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Decitabine, a DNA methyltransferase 1 inhibitor or DNA hypomethylating compound, is not readily orally bioavailable because of rapid clearance by cytidine deaminase (CDA) in the gut and liver. This dose-escalation study, guided by pharmacokinetic and pharmacodynamic observations, evaluated whether simultaneous oral administration with the novel CDA inhibitor cedazuridine increases decitabine bioavailability for the treatment of myelodysplastic syndromes. METHODS: In this phase 1 study, we enrolled patients aged 18 years or older with myelodysplastic syndromes or chronic myelomonocytic leukaemia. Eligible patients were assigned to cohorts to receive escalating oral doses of decitabine and cedazuridine. The starting dose was decitabine 20 mg and cedazuridine 40 mg. Treatment cycles lasted 28 days, with 5 days of drug administration. In cycle 1, each patient received a cohort-defined dose of oral decitabine on day -3, a 1-h intravenous infusion of decitabine 20 mg/m2 on day 1, and cohort-defined doses of oral decitabine plus cedazuridine on days 2-5. In cycles 2 and beyond, the oral decitabine and cedazuridine were given on days 1-5. The dose of cedazuridine was escalated first and decitabine was escalated once CDA inhibition by cedazuridine approached the maximum effect. The drug dose was escalated if mean decitabine area under the curve (AUC) of the oral drug was less than 90% of that for intravenous decitabine in the cohort and if no dose-limiting toxicity was observed. Dose-limiting toxicity was defined as a grade 3 or greater non-haematologic toxicity or grade 4 haematologic toxicity lasting more than 14 days and unrelated to the underlying disease. Once the decitabine AUC target range set as the primary endpoint, and established with intravenous decitabine, was reached at a dose deemed to be safe, the cohort that most closely approximated intravenous decitabine exposure was expanded to 18 evaluable patients. The primary objectives were to assess the safety of decitabine plus cedazuridine, and to determine the dose of each drug needed to achieve a mean AUC for decitabine exposure similar to that for intravenous decitabine exposure. This study is registered with ClinicalTrials.gov, number NCT02103478. FINDINGS: Between Oct 28, 2014, and Nov 13, 2015, we enrolled 44 eligible patients (of 75 screened) with previously treated or newly diagnosed myelodysplastic syndromes or chronic myelomonocytic leukaemia; 43 of the enrolled patients were evaluable. Participants were treated in five cohorts: cohorts 1-4 included six evaluable patients each; cohort 5 included 19 patients in a 13-patient expansion. Dose-dependent increases in decitabine AUC and peak plasma concentration occurred with each cohort dose escalation. There was no evident increase in toxicity compared with that reported for intravenous decitabine. Decitabine 30 mg and 40 mg plus cedazuridine 100 mg produced mean day-5 decitabine AUCs (146 ng × h/mL for decitabine 30 mg, and 221 ng × h/mL for decitabine 40 mg) closest to the mean intravenous-decitabine AUC (164 ng × h/mL). The most common grade 3 or more adverse events were thrombocytopenia (18 [41%] of 44 patients), neutropenia (13 [30%]), anaemia (11 [25%]), leukopenia (seven [16%]), febrile neutropenia (seven [16%]), and pneumonia (seven [16%]). Four (9%) patients died because of adverse events, none of which was considered drug related, and three (7%) patients died more than 30 days after discontinuing treatment because of progressive disease (two [5%]) and respiratory failure (one [2%]). INTERPRETATION: Oral decitabine plus cedazuridine emulated the pharmacokinetics of intravenous decitabine, with a similar safety profile and dose-dependent demethylation. Clinical responses were similar to intravenous decitabine treatment for 5 days. Further study of decitabine plus cedazuridine as an alternative to parenteral therapy or in combination with other new oral agents for myeloid disorders is warranted. FUNDING: Astex Pharmaceuticals, Inc.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Savona MR, Odenike O, Amrein PC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019. PMID: 30926081. doi:10.1016/S2352-3026(19)30030-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。